🔎 Trials Near Me

Home › Alzheimer's Disease › NCT05641688

[18F]PI-2620 Phase 3 Histopathological Study

RecruitingPhase 3

An Open-label, Non-randomized, Multi-center Pivotal Phase 3 Study to Evaluate the Efficacy and Safety of PET Imaging With [18F]PI-2620 for the Detection of Tau Deposition When Compared to Post-mortem Histopathology (ADvance)

Who can join

Ages 50 and older · All sexes

Full eligibility criteria
Inclusion Criteria:

Only subjects who meet all of the following criteria will be eligible for enrollment into the study:

1. Males and females aged 50 years and over
2. Have a projected life expectancy of ≤ 1 year as determined by the investigator (terminal medical condition including but not limited to end-stage dementia, end-stage congestive heart failure, end-stage chronic obstructive pulmonary disease (COPD), or end-stage cancer)
3. Written informed consent obtained from the subject and/or the subject's legally authorized representative (LAR), as applicable, to consent for study procedures and brain donation (consent consistent with the legal requirements of the State in which the subject dies)
4. Can tolerate study procedures including lying down in PET scanner. The investigator will carefully assess each subject and use medical judgment to determine whether the subject can tolerate the imaging procedure

Exclusion Criteria:

Subjects will be excluded from the enrollment if they:

1. Are receiving aggressive treatment with life sustaining measures (e.g. receiving chemotherapy; palliative chemotherapy is allowed)
2. Are known to have a structural brain lesion that would interfere either with PET imaging or pathological assessment (e.g. lesions are typically \> 2 cm at their greatest extent and may include stroke, primary or metastatic neoplasm, other tumors or cystic lesions. Subjects with a history of major stroke or traumatic brain injury or other structural lesion as well as cases with a history of primary Central Nervous System (CNS) neoplasm or known metastatic cancer must be discussed with the study sponsor prior to enrollment)
3. Have suspected encephalopathy due to alcoholism or end-stage liver disease
4. Are known to have a Glomerular Filtration Rate below \< 15 mL/min
5. Have received an investigational or approved therapy directly targeting amyloid or tau
6. Are females of childbearing potential who are pregnant, lactating or breastfeeding, or who are not using adequate contraception
7. Have implants such as implanted cardiac pacemakers or defibrillators, insulin pumps, cochlear implants, metallic ocular foreign body, implanted neural stimulators, CNS aneurysm clips and other medical implants that have not been certified for MRI, or history of claustrophobia in MRI (in case an MRI is planned to be performed)

About the study

This study is an open-label, multi-center, non-randomized pivotal Phase 3 study to assess the efficacy and safety of PET imaging with \[18F\]PI-2620 for detection of tau deposition in subjects with Alzheimer's disease (AD) and controls during lifetime when compared to histopathology obtained after death and completion of brain autopsy.

What is being tested

Sponsor: Lantheus Biosciences Ltd. · Participants: 200 · Started: Dec 1, 2022

Contact the study team

Official record on ClinicalTrials.gov — NCT05641688

Locations in the U.S.

ArizonaBarrow Neurological Institute, Phoenix
Banner Sun Health Research Institute, Sun City
CaliforniaUC Los Angeles, Los Angeles
Esperanza Clinical, Murrieta
Sutter Health, San Francisco
FloridaGaliz Research, Hialeah
K2 Medical Research, Lady Lake
K2 Medical Research, Maitland
ClinCloud Research, Melbourne
Miami Jewish Health Systems, Miami
Charter Research, Winter Park
MassachusettsAlzheimer's Disease Center, Braintree
New HampshireDarthmouth-Hitchcock Medical Center, Lebanon
New YorkVelocity Clinical Research, East Syracuse
Ichor Research, Syracuse
OhioInsight Clinical Trials LLC, Beachwood
Valley Medical Research, Centerville
TexasBaylor Research Institute, Dallas
Sante Clinical Research, Kerrville
Be Well Clinical Studies, Round Rock

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.